VELOCITY-Lung Substudy-03: A Phase 2 Study of Neoadjuvant Domvanalimab (dom)+zimberelimab (zim)+chemotherapy (chemo) or Zim+chemo Followed by Adjuvant Dom+zim or Zim in Patients with Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC).
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined